Dose-reduced thoracic radiotherapy shows promise for older and frail stage III NSCLC patients in randomized trial
By
Wei-Xiang Qi ,
Hot, fresh, and worth queueing round the block for.
Summary
This randomized open-label cohort trial by Wei-Xiang Qi and colleagues investigates whether dose-reduced thoracic radiotherapy can mitigate treatment-related toxicities while preserving oncological outcomes in older and/or frail patients with Stage III non-small-cell lung cancer (NSCLC). The study compares sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy, aiming to find a safer treatment approach for this vulnerable patient population who are often underrepresented in clinical trials.
Key quotes
· 3 pulledIn a randomized open-label trial, Wei-Xiang Qi and colleagues investigate the feasibility of dose-reduced thoracic radiotherapy to mitigate treatment related toxicities while preserving oncological outcomes in older patients with Stage III Non-small-cell Lung Cancer.
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial
This study addresses an important gap in evidence for treating older and/or frail patients with stage III NSCLC who are often excluded from standard clinical trials.
You might also wanna read
Molecular glue approach doubles survival time for pancreatic cancer patients in breakthrough trial
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1h ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·2h ago
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
A new experimental pill called daraxonrasib has shown promising results in extending survival for patients with advanced pancreatic cancer.
cnbc.com·4h ago
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·4h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·5h ago
International trial shows DNA test could help many breast cancer patients avoid chemotherapy
A new international trial presented at the American Society of Clinical Oncology conference suggests that millions of breast cancer patients
bbc.co.uk·1d ago